Aurora Spine Corporation has launched a new division named Aurora Biologics, aimed at improving spinal fusion success rates through innovative biologic solutions. This announcement was made on October 27, 2025, in Carlsbad, California, where the company is headquartered.
The creation of Aurora Biologics enhances the synergy within Aurora”s expanding spine ecosystem. This includes its renowned interspinous, lumbar, and sacroiliac fusion systems, which feature products such as ZIP, Hydra A.E.R.O., DEXA, and SiLO. By integrating mechanical and regenerative technologies, the division aims to elevate patient outcomes, streamline surgical processes, and ensure lasting fusion integrity.
Aurora Biologics is launching with a comprehensive range of allograft solutions. Each biologic is made entirely from allograft bone and is free from synthetic carriers, thus providing natural osteoconductive and osteoinductive characteristics to support reliable and high-quality bone growth. These materials are designed to be moldable and cohesive, effectively filling bony defects or enhancing fusion sites, thereby creating a natural scaffold for bone regeneration.
The products in the Aurora Biologics line are engineered to work in tandem with Aurora”s implant technologies, establishing a biologically active environment for fusion that optimizes surgical and patient outcomes.
In a statement regarding this development, Mathew Goldstone, Chief Commercial Officer of Aurora Spine, expressed, “Aurora Biologics completes our strategy of providing customers with a seamless, fully integrated portfolio. Each of our mechanical fusion systems—whether lumbar, SI, or cervical—is designed to promote bone growth. With the addition of Aurora Biologics, we now enhance the healing phase as well, allowing surgeons to deliver a fully optimized fusion procedure from start to finish.”
Trent J. Northcutt, President and CEO of Aurora Spine, highlighted that this new platform not only underscores the company”s commitment to enhancing clinical outcomes but also acts as a significant growth driver. He mentioned that by incorporating biologics into their minimally invasive product offerings, Aurora expects to see a considerable increase in revenue and profit margins.
Aurora Spine anticipates that the introduction of Aurora Biologics will establish a new standard for biologic performance in spinal care, adhering to the company”s philosophy of “Simplifying the Complex.” The products are designed to be user-friendly, clinically effective, and reflective of Aurora Spine”s ongoing dedication to innovation and quality.
For more information about Aurora Spine and its new biologics division, visit www.aurora-spine.com.
